<?xml version='1.0' encoding='utf-8'?>
<document id="30694595"><sentence text="Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor." /><sentence text="Drug-drug interaction (DDI) studies are described for tezacaftor/ivacaftor, a new cystic fibrosis transmembrane conductance regulator modulator therapy for the treatment of cystic fibrosis" /><sentence text=" Three phase I DDI studies were conducted in healthy subjects to characterize the DDI profile of tezacaftor/ivacaftor with cytochrome P450 (CYP)3A substrates, CYP3A inhibitors, and a permeability glycoprotein (P-gp) substrate" /><sentence text=" The effects of steady-state tezacaftor/ivacaftor on the pharmacokinetics (PKs) of digoxin (a P-gp substrate), midazolam, and ethinyl estradiol/norethindrone (CYP3A substrates) were evaluated"><entity charOffset="83-90" id="DDI-PubMed.30694595.s4.e0" text="digoxin" /><entity charOffset="111-120" id="DDI-PubMed.30694595.s4.e1" text="midazolam" /><entity charOffset="126-143" id="DDI-PubMed.30694595.s4.e2" text="ethinyl estradiol" /><entity charOffset="144-157" id="DDI-PubMed.30694595.s4.e3" text="norethindrone" /><entity charOffset="159-164" id="DDI-PubMed.30694595.s4.e4" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e0" e2="DDI-PubMed.30694595.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e0" e2="DDI-PubMed.30694595.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e0" e2="DDI-PubMed.30694595.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e0" e2="DDI-PubMed.30694595.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e0" e2="DDI-PubMed.30694595.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e1" e2="DDI-PubMed.30694595.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e1" e2="DDI-PubMed.30694595.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e1" e2="DDI-PubMed.30694595.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e1" e2="DDI-PubMed.30694595.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e2" e2="DDI-PubMed.30694595.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e2" e2="DDI-PubMed.30694595.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e2" e2="DDI-PubMed.30694595.s4.e4" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e3" e2="DDI-PubMed.30694595.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30694595.s4.e3" e2="DDI-PubMed.30694595.s4.e4" /></sentence><sentence text=" Effects of strong (itraconazole) and moderate (ciprofloxacin) CYP3A inhibitors on tezacaftor/ivacaftor PKs were also determined"><entity charOffset="20-32" id="DDI-PubMed.30694595.s5.e0" text="itraconazole" /><entity charOffset="48-61" id="DDI-PubMed.30694595.s5.e1" text="ciprofloxacin" /><entity charOffset="63-75" id="DDI-PubMed.30694595.s5.e2" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.30694595.s5.e0" e2="DDI-PubMed.30694595.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30694595.s5.e0" e2="DDI-PubMed.30694595.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30694595.s5.e0" e2="DDI-PubMed.30694595.s5.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s5.e1" e2="DDI-PubMed.30694595.s5.e1" /><pair ddi="false" e1="DDI-PubMed.30694595.s5.e1" e2="DDI-PubMed.30694595.s5.e2" /></sentence><sentence text=" Tezacaftor/ivacaftor increased digoxin area under the curve (AUC) by 30% but did not affect midazolam, ethinyl estradiol, or norethindrone exposures"><entity charOffset="32-39" id="DDI-PubMed.30694595.s6.e0" text="digoxin" /><entity charOffset="93-102" id="DDI-PubMed.30694595.s6.e1" text="midazolam" /><entity charOffset="104-121" id="DDI-PubMed.30694595.s6.e2" text="ethinyl estradiol" /><entity charOffset="126-139" id="DDI-PubMed.30694595.s6.e3" text="norethindrone" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e0" e2="DDI-PubMed.30694595.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e0" e2="DDI-PubMed.30694595.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e0" e2="DDI-PubMed.30694595.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e0" e2="DDI-PubMed.30694595.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e1" e2="DDI-PubMed.30694595.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e1" e2="DDI-PubMed.30694595.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e1" e2="DDI-PubMed.30694595.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e2" e2="DDI-PubMed.30694595.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30694595.s6.e2" e2="DDI-PubMed.30694595.s6.e3" /></sentence><sentence text=" Itraconazole increased the AUC of tezacaftor 4-fold and ivacaftor 15"><entity charOffset="1-13" id="DDI-PubMed.30694595.s7.e0" text="Itraconazole" /><entity charOffset="57-66" id="DDI-PubMed.30694595.s7.e1" text="ivacaftor" /><pair ddi="false" e1="DDI-PubMed.30694595.s7.e0" e2="DDI-PubMed.30694595.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30694595.s7.e0" e2="DDI-PubMed.30694595.s7.e1" /></sentence><sentence text="6-fold" /><sentence text=" Ciprofloxacin had no significant effect on tezacaftor or ivacaftor exposure"><entity charOffset="1-14" id="DDI-PubMed.30694595.s9.e0" text="Ciprofloxacin" /></sentence><sentence text=" Coadministration of tezacaftor/ivacaftor may increase exposure of sensitive P-gp substrates" /><sentence text=" Tezacaftor/ivacaftor is unlikely to impact exposure of drugs metabolized by CYP3A, including hormonal contraceptives"><entity charOffset="77-89" id="DDI-PubMed.30694595.s11.e0" text="CYP3A" /></sentence><sentence text=" Strong CYP3A inhibitors significantly increase the exposures of tezacaftor and ivacaftor"><entity charOffset="8-12" id="DDI-PubMed.30694595.s12.e0" text="CYP3A" /></sentence><sentence text="" /></document>